Apigenin for Stage IV Cancer

Also known as: 4',5,7-trihydroxyflavone, Chamomile extract

Apigenin has multi-target anti-cancer activity including kinase inhibition and immune modulation.

Mechanism of Action

Apigenin inhibits CK2, PI3K, and EGFR kinases, suppresses NF-κB and STAT3, induces apoptosis through p53 activation, and modulates tumor immunity by reducing Tregs and enhancing cytotoxic T cell function. It also inhibits angiogenesis through VEGF suppression.

General mechanism: Flavone. CD38 inhibitor (NAD+ preservation), NF-κB suppressor, CK2/PI3K inhibitor, BDNF promoter.

Current Evidence

Preclinical evidence across multiple cancer types. Parsley, chamomile, and celery are dietary sources. Clinical cancer trials limited.

Clinical Status: Preclinical. Available as supplement and in diet.

Safety Profile

Very safe. Naturally present in diet. Sedative at high doses (chamomile effect). No significant drug interactions.

Key Research Questions

View glossary entry →

← Back to Stage IV Cancer Research